UPDATE: Amedisys (AMED) Reports In-Line EPS, Revenue Tops Views; CFO to Retire

(Updated - August 2, 2016 5:47 PM EDT)

(Update corrects for adjusted EPS figure)

Amedisys (NASDAQ: AMED) reported Q2 EPS of $0.42 vs consensus of $0.42. Revenue for the quarter came in at $360 million versus the consensus estimate of $353.07 million.

Executive Retirement

On August 2, 2016, Ronald A. LaBorde, the Vice Chairman and Chief Financial Officer of the Company, announced his intention to retire from the Company and the Board of Directors as of January 2, 2017.

Paul B. Kusserow, President and Chief Executive Officer stated, “I am proud of the strong results our team delivered in the second quarter, even as we incurred deeper than anticipated software implementation disruption costs. We delivered strong growth across the board in all segments, drove improving clinical quality metrics and saw reduced employee turnover. We are continuing to progress successfully through our technology transformation and remain confident in our ability to deliver on the efficiencies that we have promised to our shareholders.”

Kusserow continued, “Lastly, while five months away, I would like to thank Ronnie LaBorde for his contribution to Amedisys which has been invaluable, particularly during the turnaround in 2014. I appreciate his contribution as a trusted colleague and friend. He will leave the company in a strong and stable position with a great future trajectory. You couldn’t ask for a better legacy.”

For earnings history and earnings-related data on Amedisys (AMED) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
• MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c